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In the previous issue of Breast Cancer Research, Metz and
colleagues characterize hematopoietic growth factor induci-
ble neurokinin-1 type (HGFIN; osteoactivin, Gpnmb, Dc-HIL)
as a gene expressed in normal mammary epithelial cells that
encodes a protein with tumor suppressor functions in breast
cancer [1]. In contrast, we have recently identified osteo-
activin as a novel mediator promoting breast cancer meta-
stasis [2] and thus feel it is premature to classify osteoactivin
as a tumor suppressor in breast cancer.
In their article, Metz et al. claim that osteoactivin expression
is “detectable in non-tumorigenic cells, but low to
undetectable in malignant cells”. This conclusion was based
on RNA expression in three breast cell lines and three
primary breast tissues. In our study, we analyzed microarray
data from a recently published data set [3] that examined
gene expression profiles of three non-malignant and 51
malignant human breast cell lines. We confirmed these
microarray data by performing quantitative real-time
polymerase chain reaction (PCR) of osteoactivin expression
in nine of these cell lines [2]. Our analysis revealed that 48
of the 51 breast cancer cell lines examined possessed
higher osteoactivin expression than normal breast MCF-12A
cells. In contrast to the data from Metz et al., the T47D and
HCC70 breast cancer cell lines possessed 2.4 and 48.5
fold higher osteoactivin expression, respectively, relative to
MCF-12A cells.
The authors also performed in situ hybridization for osteo-
activin mRNA in paraffin embedded breast biopsies. They
conclude that osteoactivin is found at higher levels in benign
tissues than in malignant tissues, and that no correlation
exists between osteoactivin expression and estrogen recep-
tor (ER) status. It must be noted that their conclusions are in
contrast to several published large scale analyses of primary
human breast tumors that are available through the online
cancer microarray database, Oncomine [4]. These studies
indicate that osteoactivin expression is significantly higher in
both breast cancer versus normal breast specimens and in
ER negative versus ER positive breast tumors [2].
Metz et al. state: “Osteoactivin is expressed in breast cancer
cells and has been associated with bone invasion, and
aggressive form of the tumor”. They repeatedly refer to Rich
et al. to corroborate this remark, however, this particular
reference does not provide any evidence to support this
statement [5]. Rich et al. were, in fact, investigating a role for
osteoactivin in promoting the invasion of a defined glioma
model. This study did not employ breast cancer cells in any
experiments, nor was bone metastasis investigated. In our
study, we report, for the first time, that ectopic osteoactivin
expression in breast cancer cells is sufficient to induce a
significant increase in the incidence of osteolytic bone
metastases in vivo.
Finally, Metz et al. refer to a study that links osteoactivin
expression to the low metastatic potential of melanoma cell
lines to support the notion that osteoactivin functions as a
tumor suppressor [6]. However, the authors have over-
looked more recent studies that identify osteoactivin as
being highly expressed in metastatic melanoma-derived cell
lines and clinical specimens. These studies report the
development of a cytotoxin-conjugated, anti-osteoactivin
antibody (CR011-vcMMAE) that is currently in Phase I/II
clinical trials as a treatment for patients with Stage III and
Stage IV melanoma [7,8].
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In summary, osteoactivin is emerging as an important, yet
controversial effector of tumor progression in several cancer
types, including breast. As such, the pursuit of rigorous,
functional studies - aimed at addressing the mechanisms of
osteoactivin-mediated effects on tumor progression and
metastasis in vivo - will be critical to assess its feasibility as a
target for therapeutic intervention in breast cancer.
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